[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-adenocarcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100520699","a-prospective-multi-center-observational-study-for-signal-c-test-evaluation-100520699",false,"NCT06059963","A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation","Inclusion Criteria:\n\n1. Subjects aged 45-84 years at time of consent\n2. Intended to undergo a standard-of-care screening colonoscopy\n3. Considered by a physician or healthcare provider as being of 'average risk' for CRC\n4. Willing to consent to blood draw prior to bowel preparatory procedures or undergoing colonoscopy ideally within 90 days of the date of the investigational blood draw.\n5. Willing to consent to follow-up for one year as per protocol\n6. Able and willing to sign informed consent\n\nExclusion Criteria:\n\n1. Undergoing colonoscopy for investigation of CRC risk symptoms\n2. Has undergone colonoscopy within preceding 9 years\n3. Positive FIT\u002FFOBT result within the previous 12 months (+\u002F- 3 months)\n4. Has completed Cologuard or Epi proColon testing within the previous 3 years.\n5. Has undergone a CT colonography in the prior 4 years.\n6. History of colorectal cancer.\n7. History of any malignancy within prior 5 years.\n8. Known diagnosis of inflammatory bowel disease (IBD), including chronic ulcerative colitis (CUC) and Crohn's disease (CD).\n9. Positive family history of colorectal cancer, defined as having a first- degree relative (parent, sibling, or child) with CRC diagnosed at age \\\u003C60 years or with more than one first-degree relative diagnosed with CRC at any age.\n10. Known hereditary\u002Fgermline risk of colorectal cancer (for example, Lynch syndrome or Hereditary Non-Polyposis CRC \\[HNPCC\\], or Familial Adenomatous Polyposis \\[FAP\\]).\n11. Any major physical trauma (e.g., disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent.\n12. Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study.\n13. Known pregnancy at informed consent, blood sample collection, and during study participation.\n14. Participation in a clinical research study in which an experimental medication has been administered or may be administered within the 30 days leading up to providing informed consent or may be administered through the time of colonoscopy.",true,"ALL","45 Years","84 Years",{"count":20,"type":21},12000,"ESTIMATED","OBSERVATIONAL","To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.",[25,26],"Colorectal Cancer","Advanced Adenocarcinoma",[28],"Advanced Precancerous Lesions","RECRUITING","2025-11-05",{"date":32,"type":33},"2025-11-10","ACTUAL",{"date":35,"type":33},"2024-01-18",{"date":37,"type":21},"2026-12-01",{"name":39,"class":40},"Universal Diagnostics","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100501390","phase-1-phase-1-study-evaluating-ba3182-in-patients-with-advanced-adenocarcinoma-100501390","NCT05808634","Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.","An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)\u002FCD3 Antibody, in Patients With Advanced Adenocarcinoma","Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma\n* Age ≥ 18 years\n* Adequate renal function\n* Adequate liver function\n* Adequate hematological function\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria:\n\n* Patients must not have clinically significant cardiac disease.\n* Patients must not have known non-controlled CNS metastasis.\n* Patients must not have active autoimmune disease or a documented history of autoimmune disease.\n* Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.\n* Patients must not incomplete recovery from the effects of major surgery or significant traumatic injury before the first dose of study treatment.\n* Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and\u002For hepatitis C.\n* Patients must not be women who are pregnant or breast feeding.","18 Years",{"count":51,"type":21},168,"INTERVENTIONAL",[54],"PHASE1","The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma",[26],[58,59,60],"Advanced","Metastatic","Cancer","2025-09-22",{"date":63,"type":33},"2025-09-25",{"date":65,"type":33},"2023-07-14",{"date":67,"type":21},"2028-09-15",{"name":69,"class":40},"BioAtla, Inc.",9]